ARWR vs RVTY · rev $829.4M vs P/E 42, rev $1.44B
Arrowhead Pharmaceuticals Inc (ARWR) versus Revvity Inc. (RVTY) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
Revvity Inc. (RVTY) is a diagnostics & research company listed on US.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported RVTY revenue for 2026-07-05 was $1.44B. Net income was $92.5M. RVTY currently screens at market cap $11.94B and trailing P/E 41.9.
ARWR currently screens at market cap $10.59B. RVTY currently screens at market cap $11.94B and trailing P/E 41.9.
Not investment advice. Open the ARWR and RVTY stock pages for the full models.
Not investment advice.